[1] A. A. Rahi, “Cutaneous Leishmaniasis in Iraq: A clinicoepidemiological descriptive study,” Sch. J. App. Med. Sci, vol. 1, no. 6, pp. 1021–1025, 2013.
[2] Z. R. Al-Ani, A. M. H. Al-Hamwandi, A. A. S. Al-Ma’aeeni, and M. K. Al-Ta’aie, “Kala-azar in Al-Anbar Governorate, Western Iraq,” Anb Med J, vol. 10, no. 1, pp. 41–49, 2012.
[3] W. H. Organization, “WHO communicable disease profile for Iraq, 2003: 39-43.” .
[4] T. Mahnaz et al., “Leishmania major: genetic heterogeneity of Iranian isolates by single-strand conformation polymorphism and sequence analysis of ribosomal DNA internal transcribed spacer,” Acta Trop., vol. 98, no. 1, pp. 52–58, 2006.
[5] A. Hailu, T. Gebre-Michael, N. Berhe, and M. Balkew, “Leishmaniasis,” Neglected Trop. Dis. Africa, pp. 87–112, 2016.
[6] Q. B. Abdulla, N. P. Shabila, and T. S. Al-Hadithi, “An An outbreak of cutaneous leishmaniasis in Erbil governorate of Iraqi Kurdistan Region in 2015,” J. Infect. Dev. Ctries., vol. 12, no. 08, pp. 600–607, 2018.
[7] M. Karami, T. Gorgani-Firouzjaee, and M. Chehrazi, “Prevalence of cutaneous Leishmaniasis in the Middle East: a systematic review and meta-analysis,” Pathog. Glob. Health, pp. 1–10, 2022.
[8] I. Mhaidi et al., “Entomological study in an anthroponotic cutaneous leishmaniasis focus in Morocco: Fauna survey, Leishmania infection screening, molecular characterization and MALDI‐TOF MS protein profiling of relevant Phlebotomus species,” Transbound. Emerg. Dis., vol. 69, no. 3, pp. 1073–1083, 2022.
[9] A. B. M. Al-Waaly and H. W. K. Shubber, “Epidemiological study of cutaneous leishmaniasis in Al–diwaniyah province, Iraq,” EurAsian J. Biosci., vol. 14, no. 1, pp. 269–273, 2020.
[10] N. Salam, W. M. Al-Shaqha, and A. Azzi, “Leishmaniasis in the Middle East: incidence and epidemiology,” PLoS Negl. Trop. Dis., vol. 8, no. 10, p. e3208, 2014.
[11] G. Nazzaro, M. Rovaris, and S. Veraldi, “Leishmaniasis: a disease with many names,” JAMA dermatology, vol. 150, no. 11, p. 1204, 2014.
[12] R. Kumar, R. A. Bumb, N. A. Ansari, R. D. Mehta, and P. Salotra, “Cutaneous leishmaniasis caused by Leishmania tropica in Bikaner, India: parasite identification and characterization using molecular and immunologic tools,” Am. J. Trop. Med. Hyg., vol. 76, no. 5, pp. 896–901, 2007.
[13] M. J. Al-Obaidi, M. Y. Abd Al-Hussein, and I. M. Al-Saqur, “Survey study on the prevalence of cutaneous leishmaniasis in Iraq,” Iraqi J. Sci., pp. 2181–2187, 2016.
[14] C. Akçalı et al., “Cutaneous leishmaniasis in Hatay,” J. Turkish Acad. Dermatology, vol. 1, no. 1, 2007.
[15] K. H. Al-Mafraji, M. G. Al-Rubaey, and K. K. Alkaisy, “Clinco-Epidemiological Study of Cutaneous Leishmaniasis in Al-Yarmouk Teaching Hospital,” IRAQI JOURNALOF COMMUNITY Med., vol. 21, no. 3, 2008.
[16] N. A. Ahmadi, M. Modiri, and S. Mamdohi, “First survey of cutaneous leishmaniasis in Borujerd county, western Islamic Republic of Iran,” East Mediterr Heal. J, vol. 19, no. 10, pp. 847–853, 2013.
[17] C. C. Stewart and W. R. Brieger, “Community views on cutaneous leishmaniasis in Istalif, Afghanistan: implications for treatment and prevention,” Int. Q. Community Health Educ., vol. 29, no. 2, pp. 123–142, 2009.
[18] S. C. F. Mendonça, “Differences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discovery,” Parasit. Vectors, vol. 9, no. 1, pp. 1–9, 2016.
[19] Z. A. Y. Al-Khayat, N. F. S. Agha, K. I. F. Alharmni, and Y. J. Khudhur, “A clinico-epidemiological study on cutaneous leishmaniasis in Erbil, Iraq (2015-2017),” Int J Res Dermatol, vol. 4, no. 1, p. 1, 2018.
[20] M. R. Yaghoobi Ershadi et al., “Epidemiological study in a new focus of cutaneous leishmaniasis in the Islamic Republic of Iran,” EMHJ-Eastern Mediterr. Heal. Journal, 9 (4), 816-826, 2003, 2003.
[21] A. M. AlSamarai and H. S. AlObaidi, “Cutaneous leishmaniasis in Iraq,” J. Infect. Dev. Ctries., vol. 3, no. 02, pp. 123–129, 2009.
[22] A. Fazaeli, B. Fouladi, and I. Sharifi, “Emergence of cutaneous leishmaniasis in a border area at south-east of Iran: an epidemiological survey,” J. Vector Borne Dis., vol. 46, no. 1, p. 36, 2009.
[23] S. Ullah, A. H. Jan, S. M. Wazir, and N. Ali, “Prevalence of cutaneous leishmaniasis in lower Dir District (NWFP), Pakistan,” J. Pakistan Assoc. Dermatologists, vol. 19, pp. 212–215, 2009.
[24] F. Norouzinezhad, F. Ghaffari, A. Norouzinejad, F. Kaveh, and M. M. Gouya, “Cutaneous leishmaniasis in Iran: results from an epidemiological study in urban and rural provinces,” Asian Pac. J. Trop. Biomed., vol. 6, no. 7, pp. 614–619, 2016.
[25] L. K. J. P. 2013; 51: 75-84. Abdellatif, MZ, El-Mabrouk K, Ewis AA. An epidemiological study of cutaneous leishmaniasis in Al-jabal Al-gharbi, “An epidemiological study of cutaneous leishmaniasis in Al-jabal Al-gharbi, Libya,” Korean J. Parasitol., vol. 51, no. 1, p. 75, 2013.
[26] A.-L. Banuls, P. Bastien, C. Pomares, J. Arevalo, R. Fisa, and M. Hide, “Clinical pleiomorphism in human leishmaniases, with special mention of asymptomatic infection,” Clin. Microbiol. Infect., vol. 17, no. 10, pp. 1451–1461, 2011.
[27] C. da Silva Santos and C. I. Brodskyn, “The role of CD4 and CD8 T cells in human cutaneous leishmaniasis,” Front. public Heal., vol. 2, p. 165, 2014.
[28] E. Kamali-Sarvestani, M. Rasouli, H. Mortazavi, and B. Gharesi-Fard, “Cytokine gene polymorphisms and susceptibility to cutaneous leishmaniasis in Iranian patients,” Cytokine, vol. 35, no. 3–4, pp. 159–165, 2006.
[29] J. R. Ramírez et al., “Diagnosis of cutaneous leishmaniasis in Colombia: the sampling site within lesions influences the sensitivity of parasitologic diagnosis,” J. Clin. Microbiol., vol. 38, no. 10, pp. 3768–3773, 2000.